Barclays’s Checkpoint Therapeutics CKPT Stock Holding History

Barclays’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,294,777	Closed	-$5.23M	–	5295
2025 Q1	$5.23M	Buy	+1,294,777	New	+$4.32M	﹤0.01%	1874
2021 Q4	–	Sell	-822	Closed	-$27K	–	4183
2021 Q3	$27K	Sell	822 -4,443	-84%	-$131K	﹤0.01%	4297
2021 Q2	$156K	Buy	5,265 +938	+22%	+$26K	﹤0.01%	3654
2021 Q1	$136K	Buy	4,327 +2,656	+159%	+$89K	﹤0.01%	3876
2020 Q4	$44K	Sell	1,671 -392	-19%	-$9.92K	﹤0.01%	4458
2020 Q3	$55K	Sell	2,063 -175	-8%	-$4.2K	﹤0.01%	4550
2020 Q2	$45K	Buy	2,238 +1,125	+101%	+$20.5K	﹤0.01%	4966
2020 Q1	$17K	Sell	1,113 -1,334	-55%	-$23.6K	﹤0.01%	5683
2019 Q4	$42K	Buy	2,447 +1,241	+103%	+$20.8K	﹤0.01%	5781
2019 Q3	$30K	Sell	1,206 -280	-19%	-$7.68K	﹤0.01%	6108
2019 Q2	$45K	Buy	+1,486	New	+$58.3K	﹤0.01%	6142

Barclays's CKPT Position: Q2 2025 in Review

Barclays sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 1,294,777 shares — an estimated $5.23M sold.

Barclays first reported a position in CKPT in Q2 2019 and held it in 11 quarters. The position peaked at $5.23M in Q1 2025. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.

Barclays reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
Barclays sold 1,294,777 Checkpoint Therapeutics shares in Q2 2025, an estimated $5.23M.
Barclays first reported a position in Checkpoint Therapeutics in Q2 2019 and held it in 11 quarters.
Barclays's Checkpoint Therapeutics position peaked at $5.23M in Q1 2025.
0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.